R. Mass - Concepedia

Author

R. Mass

Duke University

Also Known As

R D Mass, R Mass, R. D. Mass, R. Mass, R.D. Mass, ROBERT D. MASS, Robert D Mass, Robert D. Mass, Robert Mass

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Duke University Oregon Health & Science University The University of Texas MD Anderson Cancer Center Vanderbilt-Ingram Cancer Center Memorial Sloan Kettering Cancer Center

About

R. Mass is an author at Duke University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	1.1K
2	Health Sciences	7	7	604
3	Cell Biology	2	2	25
4	Engineering	1	1	45
5	Endocrinology	1	1	68

R. Mass

Publications

Citations

H-Index

Page 1

	Year	Citations
Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod, Journal of Clinical Oncology	2005	932
Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer Fairooz F. Kabbinavar, Julie Hambleton, R. Mass, Journal of Clinical Oncology	2005	687
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer Roy S. Herbst, David H. Johnson, Eric D. Mininberg, Journal of Clinical Oncology	2005	535
Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab R. Mass, Michael F. Press, Steven M. Anderson, Clinical Breast Cancer Her2 DetectionBreast OncologyCancer DetectionMedicinePathology	2005	364
Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab Noël Dybdal, Grazyna Leiberman, Steven M. Anderson, Breast Cancer Research and Treatment Breast OncologyOncologyMedicinePathologyHer2 Gene Amplification	2005	212
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107 Axel Grothey, Eric Hedrick, R. Mass, Journal of Clinical Oncology	2008	171
Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma Howard Safran, Margaret M. Steinhoff, Shamlal Mangray, American Journal of Clinical Oncology	2001	162
TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) Roy S. Herbst, Diane Prager, Róbert Hermann, Journal of Clinical Oncology	2004	131
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease Ralph Zinner, Bonnie S. Glisson, Frank V. Fossella, Lung Cancer OncologyPhase Ii TrialPathologyBronchial NeoplasmHer2-overexpressing Disease	2003	124
The role of HER-2 expression in predicting response to therapy in breast cancer. R. Mass PubMed	2000	93

Page 1